Precipio (PRPO) Q1 2026 earnings summary

Executive summary

• Focused on cancer diagnostics, integrating clinical laboratory services with proprietary product development to drive innovation and operational efficiency.

• Operates a single segment with two complementary divisions: pathology services and diagnostic products.

• Pathology services saw a 63% increase in cases processed year-over-year, driving revenue growth.

Financial highlights

• Net sales for Q1 2026 were $6.7 million, up 36% from $4.9 million in Q1 2025, driven by higher diagnostic service volumes.

• Gross profit increased to $2.7 million from $2.1 million, but gross margin declined to 41% from 43% due to lower average price per case.

• Operating loss widened to $1.4 million from $0.9 million year-over-year.

• Net loss was $1.4 million, or $(0.81) per share, compared to $0.9 million, or $(0.59) per share, in the prior year.

• Cash at quarter-end was $2.6 million, down slightly from $2.7 million at year-end 2025.

Outlook and guidance

• Substantial doubt remains about the ability to continue as a going concern over the next twelve months without additional revenue growth or financing.

• Future performance depends on executing the business plan, generating revenue, and securing financing.